The Endocrine Gland Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Endocrine Gland Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Endocrine Gland Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Endocrine Gland Disorders and features dormant and discontinued products.
GlobalData tracks 43 drugs in development for Endocrine Gland Disorders by 33 companies/universities/institutes. The top development phase for Endocrine Gland Disorders is preclinical with 23 drugs in that stage. The Endocrine Gland Disorders pipeline has 42 drugs in development by companies and one by universities/ institutes. Some of the companies in the Endocrine Gland Disorders pipeline products market are: Promomed Rus, Daewon Pharmaceutical and Genflow Biosciences.
The key targets in the Endocrine Gland Disorders pipeline products market include NAD Dependent Protein Deacetylase Sirtuin 6, NPC1 Like Intracellular Cholesterol Transporter 1, and Prelamin A/C.
The key mechanisms of action in the Endocrine Gland Disorders pipeline product include NAD Dependent Protein Deacetylase Sirtuin 6 Activator with two drugs in Preclinical. The Endocrine Gland Disorders pipeline products include six routes of administration with the top ROA being Oral and seven key molecule types in the Endocrine Gland Disorders pipeline products market including Small Molecule, and Gene Therapy.
Endocrine Gland Disorders overview
Endocrine gland disorders are medical conditions that affect the function of the endocrine system, which is a network of glands that produce and release hormones that regulate many body processes. Some common endocrine disorders are diabetes, hyperthyroidism, hypothyroidism, Cushing’s disease, and polycystic ovary syndrome (PCOS). These disorders can result from various causes, such as tumors, genetic factors, hormonal imbalances, or autoimmune reactions. Endocrine disorders can cause symptoms such as weight changes, fatigue, mood swings, reproductive problems, and growth abnormalities. Endocrine disorders are diagnosed by blood tests that measure the levels of hormones or other markers in the bloodstream. Treatment options depend on the type and cause of the disorder, but may include medication, surgery, radiation therapy, or lifestyle changes.
For a complete picture of Endocrine Gland Disorders’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
